×
Bio-Rad Laboratories (BIO) is scheduled to report its third-quarter 2026 results on Wednesday, November 4, 2026, after the market close. Wall Street consensus points to non-GAAP earnings of about $2.23 per share on revenue near $649.9 million .
HSCS declined -11.24% during regular market hours to roughly $3.16, giving back a portion of the prior session's +13.7% surge. The pullback follows profit-taking after the definitive proxy filing advanced its all-stock merger with Fortitude Mining, a Zcash-focused digital asset miner, with a shareholder vote set for November 19.
PMI is trading down about -23.4% to roughly $7.38 during the regular session, versus a prior close of $9.63. The decline stems from continued extreme volatility in this low-float (~2.3M share) micro-cap, with no single company filing behind the drop.
BIO has rallied sharply in recent weeks on digital PCR momentum and steady diagnostics demand, yet weak life science spending and a premium valuation temper the move. FDS has delivered accelerating organic growth and record subscription value, powered by rising demand for AI-ready financial data, but faces margin compression.
10x Genomics (TXG) fell -7.12% to $70.21, down from the prior session's close of $75.59, during regular market hours. Selling pressure built ahead of the company's Q2 earnings release, with investors reducing exposure into the catalyst.
ALMR is down -8.97% (about -$2.82) to roughly $28.63 during regular market hours, giving back much of the prior session's +11.68% surge to $31.45. The primary driver is profit-taking after the sharp one-day rally pushed shares near their 52-week high, with no new company news to sustain the advance.
Fourth-quarter revenue was $434.9 million, down 1.7% year over year and slightly ahead of analyst consensus. Adjusted EPS (earnings per share) came in at $0.83, beating estimates but falling 14.4% from the prior-year quarter.
Abbott reported adjusted earnings per share (EPS) of $1.42 , up 9.2% from $1.30 a year ago and slightly below the consensus estimate of $1.43. Revenue rose 14.5% on a reported basis to $13.01 billion , with comparable (organic) sales growth of 7.0%, led by double-digit gains in Electrophysiology and Rhythm Management.
ABT fell -3.26% to $99.11 from a prior close of $102.45, dropping in premarket trading and holding losses during the regular session. Primary catalyst: Abbott announced plans to spin off its Nutrition business (Similac, Ensure, Pedialyte) into a separate public company by the end of 2027.
DexCom shares traded near $80 in late October, down roughly 9.4% over the trailing 30 days after slipping from about $89 in mid-September. The pullback has unfolded despite solid fundamentals: second-quarter 2026 revenue rose 13% year over year, and the company raised the low end of its full-year guidance.
Integra LifeSciences (IART) shares fell roughly 20.6% over the last 30 days, declining from a closing price near $15.59 to about $12.38. The sharpest move came on October 2, 2026, when the stock dropped about 21% after the company pre-announced third-quarter results and cut its full-year guidance.
IART fell -5.93% to $12.54 during regular trading on Oct 21, from a prior close of $13.33. The drop followed Q3 earnings reported premarket: adjusted EPS of $0.59 beat the $0.56 estimate, but revenue of $411.2M missed the $413.2M consensus.
DXCM fell -5.8% during regular trading, dropping from a prior close of $85.74 to roughly $80.77. The decline occurred in the regular session, tracking a broad medtech and healthcare-sector pullback.
LUCD is down -14.9% intraday to about $0.32, extending the prior session's -21% drop, with the selling occurring during regular market hours after a briefly higher premarket open. No company-specific headline accompanied today's move, which caps a roughly -46% slide over the past week.
The central target of $4.00 is the arithmetic mean of five verified analyst price targets, which range widely from $2.00 to $9.50. At a recent price near $0.38 , reaching $4.00 would require roughly 960% upside — a very large move.
Medicare coverage is the pivotal catalyst. Lucid Diagnostics is awaiting a final Local Coverage Determination (LCD), a formal decision on whether Medicare will pay for its EsoGuard test, which management calls its most important pending milestone. Reimbursement infrastructure is building. A Medicare advisory panel recently recommended maintaining EsoGuard's payment basis, and a new procedural code and diagnosis code are advancing through approval.
The $2.30 central target is the arithmetic mean of three verified, current analyst price targets: $4.00 (H.C. Wainwright), $1.90 (Alliance Global Partners), and $1.00 (Canaccord Genuity). With the latest verified price near $1.12, reaching $2.30 implies roughly 105% upside — a very large move by any standard.
QSI is down -8.04% in regular trading Monday, falling to about $1.03 from Friday's $1.12 close. Primary catalyst: Wall Street Zen downgraded Quantum-Si from "hold" to "sell," triggering selling pressure after the open.
Proteus is the pivotal catalyst. Quantum-Si's next-generation protein sequencing platform has been delayed to a commercial launch in Q2 2027, making execution on this timeline the single most important factor for the stock forecast. Amino-acid coverage is expanding. The company reported detection of 19 of the 20 standard amino acids in early October 2026 and targets full coverage by year-end, a key technical milestone investors are watching.
The central price target of $100 is the arithmetic mean of roughly ten current, attributable analyst price targets, rounded to a clean level. The latest verified price is about $76.52, implying a required move of roughly 31% — a substantial but not extreme gain.
Previous
23 of 31
Next